
Review Article

The Application of Platelet-Rich Plasma Injection in Genito-Urinary Medicine

Al Fadhil A. Omer

Al Neelain University, Khartoum, Sudan.

Introduction

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of platelet-rich plasma protein derived from whole blood, centrifuged to remove red blood cells. Evidence for benefit is poor as of 2016.

Medical use

PRP has been investigated and used for chronic tendinitis, osteoarthritis, in oral surgery, and in plastic surgery. It has not been found to be useful in rotator cuff disease. Tentative evidence supports its use in osteoarthritis (OA) of the knee.

A 2009 review found few randomized controlled trials that adequately evaluated the safety and efficacy of PRP treatments and concluded that PRP was "a promising, but not proven, treatment option for joint, tendon, ligament, and muscle injuries". As compared to other conservative treatments for non-surgical orthopedic illnesses (e.g. steroid injection for plantar fasciitis), evidence does no support the use of PRP as a conservative treatment.

A 2010 Cochrane review of use in sinus lifts during dental implant placement found no evidence of benefit. A 2013 review stated more evidence was needed to determine effectiveness for hair regrowth.

A 2014 Cochrane review of PRP in musculoskeletal injuries found very weak evidence for a decrease in pain in the short term, and no difference in function in the short, medium or long term. There was weak evidence that suggested that harm occurred at comparable, low rates in treated and untreated people.[2] Similarly, another 2017 review for treating pain on skin graft donor sites found the evidence for benefit was poor.

It has not been shown to be useful for bone healing. A 2016 review of PRP use to augment bone graft found only one study reporting a difference in bone augmentation, while four studies found no difference.

Since 2004, proponents of PRP therapy have argued that negative clinical results are associated with poor-quality PRP produced by inadequate single spin devices. The fact that most gathering devices capture a percentage of a given thrombocyte count could bias results, because of inter-
individual variability in the platelet concentration of human plasma and more would not necessarily be better. PRP has also been injected into the vagina, in a procedure called "O-shot" or "orgasm shot" with claims that this will improve orgasms. There is no evidence, however, to support these claims.

**Adverse effects**

There are no studies to date that have reliably documented adverse effects associated with PRP treatment, possibly due to poor and inconsistent methodology. In 2019, Health Canada stated that most autologous cell therapies have little evidence showing they work and can pose risks, such as cross-contamination between people if equipment is not sterilized properly or potentially dangerous immune reactions. There are efforts to stop Canadian clinics from offering these types of services.

**Composition**

There are four general categories of preparation of PRP based on its leukocyte and fibrin content: leukocyte-rich PRP (L-PRP), leukocyte reduced PRP (P-PRP; leukocyte reduced or pure PRP), leukocyte platelet-rich fibrin and pure platelet-rich fibrin. The efficacy of certain growth factors in healing various injuries and the concentrations of these growth factors found within PRP are the theoretical basis for the use of PRP in tissue repair. The platelets collected in PRP are activated by the addition of thrombin and calcium chloride, which induces the release of the mentioned factors from alpha granules.

The growth factors and other cytokines present in PRP include:
* platelet-derived growth factor
* transforming growth factor beta
* fibroblast growth factor
* insulin-like growth factor 1
* insulin-like growth factor 2
* vascular endothelial growth factor
* epidermal growth factor
* Interleukin 8
* keratinocyte growth factor
* connective tissue growth factor

**Manufacturing**

PRP is prepared by taking blood from the person, and then putting it through two stages of centrifugation designed to separate PRP from platelet-poor plasma and red blood cells. This is usually done by the clinic offering the treatment, using commercially available kits and equipment. The resulting substance varies from person to person and from facility to facility, making it difficult to understand how safe and effective any specific use is.

Omer, 2019, 4 (11)
Society and culture
The cost of a PRP treatment in the U.S. has been quoted as $1000 out-of-pocket expenses, as it is usually not covered by health insurance. PRP has received attention in the popular media as a result of its use by athletes. Use in an office setting is not approved by the FDA.
In the 2010s, contentious cosmetic procedures marketed under the name of "vampire facials" grew in popularity, fueled by celebrity endorsement. These "vampire facials" generally center on PRP treatment, and usually (but not always) involve microneedling.

Doping
Some concern exists as to whether PRP treatments violate anti-doping rules. As of 2010 it was not clear if local injections of PRP could have a systemic impact on circulating cytokine levels, affecting doping tests and whether PRP treatments have systemic anabolic effects or affect performance. In January 2011, the World Anti-Doping Agency removed intramuscular injections of PRP from its prohibitions after determining that there is a "lack of any current evidence concerning the use of these methods for purposes of performance enhancement".

PRP use to induce restoration of mice testes
Zaporozhan Valeriya and his colleagues used PRP to induce morphofunctional restoration of mice testes following doxorubomycine hydrochloride exposure. According to the World Health Organization (WHO), about 8% of couples during the reproductive period of life are faced with the problem of infertility. In technologically advanced countries such as USA, Germany, Denmark etc. about 15% of couples suffers from infertility. Data obtained over the last 20 years show about 30% of fertilization problems cases are caused only by male factor, according to some sources -about 50% of cases. So, the efforts of doctors and researchers are aimed at finding of effective treatment methods for spermatogenesis disorders. Using the platelet-rich plasma (PRP) is one of the promising technologies. PRP is a plasma with platelets’ concentration more than 1000000/mcl since it was proved that only this concentration has stimulating effect. PRP has therapeutic effect due to the presence of growth factors. In addition, interest to the PRP is high because it is 100% biocompatible, safe, wouldn’t cause patient’s infection, as it is made with patients’ own blood.
Their published article in the Journal of Experimental and Clinical Medicine (2014) stated that the efforts of doctors and researchers are aimed at finding of effective treatment methods for spermatogenesis disorders. Platelet-rich plasma (PRP) has therapeutic effect due to the presence of growth factors. This work aimed to investigate the function of PRP on mice males’ gonads in experimental toxic affection. After toxic affection of the gonads by doxorubomycine hydrochloride (DH) mice got three injections of PRP. PRP was isolate from whole blood with the processing unit SmartPrep (Harvest Corp.). The introduction of PRP under the skin of scrotum renews the testis microstructure and the state of spermatogenic epithelium in mice, normalizes the amount and functioning of the Sertoli cells. This effect, probably, is conditioned by the activity of the growth factors, which freed from platelets’ α-granules after the PRP injection.
Doxorubomicine hydrochloride administration caused the development of testis tissue affection

Omer, 2019, 4 (11)
as the result of toxic influence of DH which is used for cancer chemotherapy. DH quickly penetrates the cell, interacts with DNA, prevents the nucleic acids synthesis and inhibits mitotic activity. Cancer treatment cause a variety of toxic effects detected in testis. In our research main manifestation of this process was approximately 40% decrease of the number of spermatogonia what indicates the spermatogenesis depression. As a result, the number of newly formed spermatocytes and sperm reduced dramatically. Also development of inflammatory reaction both in the interstitium and basement membrane was mentioned as confirmed by the increased in the specific area of interstitium, the presence of protein detritus in the seminiferous tubules, detachment of spermatogenic epithelium, and basement membrane thickening. Affection of the tubule was heterogeneous in nature and depended on the stage of spermatogenesis, which was at the time of DH administration. The obtained data are similar to those of toxic damage of testicles of various origin. The results of pathomorphological and morphometric investigations showed restoration of experimental animals’ testicular microstructure after exposure of PRP. The spermatogenesis resumed, and Sertoli cell number and function normalized. The width of ducts of seminiferous tubules reached indexes of the control testis, in many ducts a large number of newly formed sperm revealed. It indicates the renewal of the morphofunctional state of gonads after the use of PRP in case of experimental toxic injury. Obviously, this effect is due to the activity of growth factors that are released from α-granules of platelets after PRP injection: Epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), etc. The basis for this conclusion is a list of the properties of these biologically active substances: the stimulation of cell growth and differentiation, enhancement of angiogenesis and collagen synthesis, antiapoptotic effect, accelerating cell migration and others. Given the fact that, e.g., cancer chemotherapy leads to hypogonadism and reduced fertility, and such patients are forced to take samples of seminiferous epithelium in sperm bank for cryopreservation and further treatment, the use of PRP will help to avoid additional financial costs and anxiety. Thus, one can assume the use of platelet-rich plasma is an effective method of restoring the state of the gonads after toxic damage.

**PRP use to improve impairment of rat testis**

Dehghani and his co-workers reported that PRP has a potential effect on tissue repair through proliferation and differentiation of tissue progenitor cells. The aim of this study was to evaluate the effect of PRP on the testis structure and function in infertile rat model by stereological method. Thirty-two male rats were divided into four groups. Infertility was induced by the administration of busulfan (BUS) (10mg/kg, I.P., single dose). PRP (80μl, testis local injected, single dose) was administered for the subjects. After 48 days, semen analysis was performed and blood samples were taken from the heart to measure the testosterone. Then, the left testis was removed, fixed, embedded, sectioned, and stained by H&E; after that the testes were analyzed. The results showed that BUS can decrease the sperm count, motility, normal morphology, length of the spermatozoon tail, volume of the testis, seminiferous tubules, germinal epithelium height, and the number of spermatogenesis lineage cells in comparison with the control group (p < 0.01). PRP increased the number of spermatogenic stem cell, count, motility and tail length of the sperm and testosterone level in BUS-treated animal significantly, but it did not have any effect

**Omer, 2019, 4 (11)**
on the volume of the testis, germinal epithelium height, Sertoli and Leydig cells number, and seminiferous tubules length. It concluded that PRP can improve the structural and functional impairment of the testis in treatment by BUS.

Clinical applications of PRP in various gynecological disorders

A.S. Dawood (2018) presented a theoretical and practical appraisal on the current clinical applications of PRP in gynecology. A literature search was done using PubMed, Google Scholar, Clinical Key, and Medline to identify studies investigating the uses of PRP in gynecology. The search period was from January 1, 2000 to December 31, 2017. The search words were “platelet-rich plasma,” “implementations,” “uses,” “endometrium,” “infertility,” and “gynecology.” The studies found were case series, case reports, letters, and pilot studies with a small sample size. No randomized clinical trials with a suitable number of patients were found in the search results. The preparation of PRP is an outpatient procedure that involves a blood draw, preparation of the PRP, and the injection of PRP into the diseased area. Multiple methods have been developed for PRP preparation, with variation in the speed and timing of centrifugation. The following steps present a representative method of preparing PRP:

1. Venous blood (15–50 mL) is drawn from the patient's arm in anticoagulant-containing tubes.
2. The recommended temperature during processing is 21°C–24°C to prevent platelet activation during centrifugation of the blood.
3. The blood is centrifuged at 1,200 rpm for 12 minutes.
4. The blood separates into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells.
5. The upper and intermediate buffy layers are transferred to an empty sterile tube. The plasma is centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube.
6. The upper two-thirds of the plasma is discarded because it is platelet-poor plasma.
7. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP.
8. The PRP is now ready for injection. Approximately 30 mL of venous blood yields 3–5 mL of PRP.
9. The affected area is disinfected before the PRP injection.
10. Providing assurance to the patient and discussing the procedure make the injection easier and less painful.
11. PRP stimulates a series of biological responses, and the injection site may become swollen and painful for roughly 3 days.

PRP preparations can be classified according to the preparation method, the content of the sample, and the proposed application. Preparations vary in terms of centrifugation speed, centrifugation time, and anticoagulant use, while the content varies depending on the predominant constituent (e.g., platelets, leukocytes, or growth factors).

After centrifugation of whole blood, four types of preparations can be obtained. This classification is based on cell content and fibrin density, and was recommended by a multi-
disciplinary consensus committee. Another classification of PRP preparations was based on the presence or absence of white blood cells, their activation status, and platelet concentration. A newer classification of PRP preparations was called the DEPA (dose of injected platelets, efficiency of production, purity of the PRP, activation of the PRP) classification.

Platelets contain high concentrations of cytokines and growth factors stored within α-granules. These growth factors include platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, platelet-derived angiogenic factor, transforming growth factor beta, fibroblast growth factor, epidermal growth factor, connective tissue growth factor, and interleukin-8. In addition to growth factors, platelets contain other substances, such as fibronectin, vitronectin, and sphingosine 1-phosphate, that initiate wound healing.

Platelet activation triggers the release of these growth factors by a variety of substances or stimuli such as thrombin, calcium chloride, and collagen. Each method influences both the physical form of PRP and the amount of growth factors released, as well as the kinetics of release. No evidence has been found regarding the ideal concentration of activator required to trigger the optimal release of growth factors during the activation process of PRP, and different concentrations may therefore lead to different results.

The mechanisms of PRP have not been completely elucidated, but laboratory studies have shown that the high concentration of growth factors in PRP can potentially speed up the healing process. Growth factors promote wound healing by initiating the following stages: tissue necrosis resolution, chemotaxis, cell regeneration, cell proliferation and migration, extracellular matrix synthesis, remodeling, angiogenesis, and epithelialization.

PRP is superior to recombinant human growth factor because platelet activation leads to the release of multiple growth factors and differentiation factors. Recently, the fibrin framework present over platelets was found to support the regenerative matrix, leading to the rapid establishment of the proper morphological and molecular configuration for wound healing. Tissue repair begins with clot formation and is followed by platelet degranulation with the release of platelet growth factors. These are necessary and well-regulated processes to achieve wound healing. PRP preparations are used in gynecology for various diseases based on its known mechanisms, which involve the wound healing process and the initiation of inflammatory reactions.

**PRP in skin lesions and wound healing**

Due to the ability of PRP to promote angiogenesis and wound healing, it is widely used in dermatology for purposes including the treatment of ulcers, scars, and alopecia. With this in mind, PRP was tested by Tehranian et al in wound healing in high-risk women undergoing cesarean sections. They applied PRP in 70 patients and compared them to 71 control cases without PRP application. The inclusion criteria were a body mass index (BMI) >25 kg/m², prior cesarean section, diabetes, twin pregnancy, use of corticosteroid medication, and anemia. They found a greater reduction in the redness, edema, ecchymosis, discharge, approximation score than in the control group (85.5% reduction in the PRP group vs. 72% in the control group) (p<0.001). They concluded that PRP was an effective therapeutic approach for wound healing, and faster wound healing can be expected when PRP is used due to the presence of more

**Omer, 2019, 4 (11)**
platelets and growth factors. Another study was conducted of 55 patients undergoing major gynecological surgery, in whom PRP was directly applied to the surgical site. The authors found that autologous platelet grafts applied in gynecological surgery were effective for pain reduction and were not associated with any adverse effects.

**PRP in cervical ectopy**

Hua et al conducted a randomized clinical study to compare the effectiveness of autologous PRP application to that of laser treatment for benign cervical ectopy. They applied PRP twice on the area of cervical erosion with a 1-week interval in 60 patients, while laser treatment was used in the other 60 patients. They found that the complete cure rate was 93.7% in the PRP group and 92.4% in the laser group ($p>0.05$). The mean time to re-epithelialization was significantly shorter in the PRP group ($p<0.01$). The rate of adverse treatment effects (i.e., vaginal discharge or vaginal bleeding) was much lower in the PRP group than in the laser group ($p<0.01$). They concluded that autologous PRP application appeared promising for the treatment of cervical ectopy in symptomatic women, as it yielded a shorter tissue healing time and milder adverse effects than laser treatment.

**PRP in vulvar dystrophy**

PRP has been tried in many dermatological and autoimmune conditions nonresponsive to corticosteroids, such as lichen sclerosis (LS) and eczema. LS affects the vulva and causes extensive scarring, with progressive loss of the labia minora, sealing of the clitoral hood, and burying of the clitoris. LS also causes progressive pruritus, dyspareunia, and genital bleeding. It has a considerable impact on the quality of life of affected patients by disturbing physical activity, sexual pleasure, and causing emotional and psychological problems. This condition is treated by topical and systemic corticosteroids. Application of PRP in cases of LS resistant to steroid therapy was tried by Behnia-Willison et al. in 28 patients with LS. They injected PRP into the vulva in a fanning pattern. Patients received three PRP treatments 4 to 6 weeks apart and again at 12 months. Nearly all patients exhibited clinical improvements in the size of their lesions, and in 28.6% of the patients, the lesions disappeared completely after PRP treatment. Minimal pain and no complications were reported. They concluded that PRP injections could therefore be considered an effective therapy for LS.

**PRP in reconstructive surgery for vulvar cancer**

Morelli et al. conducted a retrospective study of patients who underwent surgery for vulvar cancer (radical vulvectomy). The aim of their study was to evaluate the efficacy of platelet gel application in women after radical surgery. They divided patients into two groups: group A (n=10), who had platelet gel placed on the vaginal breach during reconstructive surgery, and group B (n=15), who underwent only surgical treatment. They found significantly lower rates of wound infection ($p=0.032$), necrosis of vaginal wounds ($p=0.096$), and wound breakdown ($p=0.048$) in group A than in group B. They also found a reduction in the postoperative fever rate, a shorter hospital stay, and faster wound healing in group A, which received PRP gel treatment. They concluded that platelet gel application before vulvar reconstruction represented an effective strategy for preventing wound breakdown after surgery to treat locally advanced vulvar cancer.

**Omer, 2019, 4 (11)**
PRP in urogenital disorders

(1) PRP in genital fistulae

Genital fistulae are treated by many modalities, as listed by Bodner-Adler et al. in a systemic review that assessed conservative and surgical treatments. They found that small fistulae could be treated conservatively with various therapies, including PRP, with success rates ranging from 67% to 100%.

PRP has been tried in the treatment of vesicovaginal fistulae as a novel, minimally invasive approach for the closure of genital fistulae. Shirvan et al. [23], in a series of 12 patients, injected PRP around the fistula into the tissue, and platelet-rich fibrin (PRF) glue was interpositioned in the tract. They followed the cases for 6 months and found that 11 patients were clinically cured, with normal findings on transvaginal physical examinations and cystography. They concluded that autologous PRP injection and PRF glue interposition offered a safe, effective, and novel minimally invasive approach for the treatment of vesicovaginal fistulae that obviated the need for open surgery.

Mongardini et al. presented a case of a complicated iatrogenic low rectovaginal fistula treated by interposition of buccal mucosa and apposition of PRP. Similarly, Gottgens et al. performed PRP injections into the fistula tract after a mucosal advancement flap in 10 patients with Crohn disease-related high perianal fistulae. They found that healing of the fistula took place in 70% of cases (95% confidence interval, 33%–89%) at 1 year. One patient (10%) experienced recurrence, and in two patients (20%), the fistula persisted after treatment. They concluded that this procedure was moderately successful in Crohn disease fistulae, with a success rate of 70%, and suggested that further studies were needed.

(2) PRP in genital prolapse and urinary incontinence

Both absorbable and nonabsorbable vaginal implants used in pelvic floor reconstructive procedures have numerous serious adverse effects. PRF is a mixture of platelets, leukocytes, cytokines, and circulating stem cells that is optimal for stimulating fibroblast migration and proliferation. This mixture causes rapid remodeling and connective tissue growth after vaginal surgery.

Gorlero et al. conducted a prospective observational study of 10 consecutive women requiring surgery for prolapse recurrence (stage II or higher). They operated on the cases and performed PRF injections. The success rate was 80% with complete symptom relief. Sexual activity increased by 20% without dyspareunia. They concluded that the use of PRF for site-specific prolapse repair was associated with good functional outcomes. Furthermore, Medel et al. found that the attachment of fibroblasts to vaginal meshes significantly increased after coating the meshes with PRP in vitro.

Recently Chrysanthopoulou et al. summarized the existing evidence from animal experimental and clinical studies regarding the potential role of PRP in treating genital prolapse. They concluded that PRP restores the anatomy and function of pelvic ligaments, but no evidence has yet emerged to support or oppose PRP use in women suffering from genital prolapse. Similarly, Nikolopoulos et al. summarized studies advocating the use of PRP in urinary incontinence resulting from damage to the pubourethral ligament. They found that PRP helps to regulate tissue reconstruction and the restoration of pubourethral ligament strength, but the studies did not provide sufficient evidence to justify its use.

Omer, 2019, 4 (11)
In contrast, another study was conducted to evaluate whether autologous platelet gel application during anterior colporrhaphy increased the collagen content of the pubocervical fascia, resulting in more durable repair. The researchers applied autologous platelet gel to the surgical site during anterior colporrhaphy in nine patients. Biopsy specimens from the anterior vaginal wall during surgery and 3 months postoperatively were collected. They found that no significant increase had occurred in collagen content at 3 months after the operation, and concluded that autologous platelet gel did not increase collagen levels or improve the durability of the repair.

**PRP in reproductive medicine**

1) **PRP in premature ovarian failure**
Premature ovarian failure (POF) refers to loss of normal function of the ovaries before age 40, accompanied by the loss of fertility. A team of researchers at Harvard University injected murine ovaries with growth factors, and mature eggs appeared to develop from ovarian stem cells. They stated that the introduction of isolated growth factor-bearing platelets directly into the ovaries might trigger a resurgence in oocyte production. PRP therapy is investigated in women with POF, infertile women more than 35 years of age, and women with low ovarian reserve. Treatment with PRP is referred to as ovarian rejuvenation; in this procedure, PRP is injected into the ovary under ultrasound guidance, similarly to ovum retrieval in *in vitro* fertilization (IVF). This modality of treatment is still being investigated in trials. Pantos et al. at the annual European Society of Human Reproduction and Embryology conference held in 2016 in Helsinki, Finland, introduced this modality (ovarian rejuvenation). They injected PRP in eight perimenopausal/POF women with poor ovarian reserve. They found successful ovarian rejuvenation 1–3 months after PRP treatment. All cases underwent natural IVF cycles with follicles of 15.20±2.05 mm in diameter, the resulting oocytes were inseminated by intracytoplasmic sperm injection (ICSI), and all resulting embryos were cryopreserved.

2) **PRP in ovarian torsion**
In an animal model, 60 adult female rats were subjected to ischemia and bilateral adnexal torsion for 3 hours. Intraperitoneal PRP was administered 30 minutes prior to ischemia in one group, while the other group was not injected with PRP. Detorsion was then done, and oxidative stress levels, histopathological changes, and reperfusion injuries were lower in the PRP group than in the other group. The researchers concluded that PRP was effective for the prevention of ischemia and reperfusion damage in rat ovary.

3) **PRP in refractory endometrium**
The endometrium plays an important role in achieving optimal outcomes of assisted reproductive technologies. Endometrial growth following inadequate ovarian stimulation may be insufficient, leading to poor results of IVF/ICSI cycles. Various strategies been suggested to improve endometrial thickness, especially in resistant cases. PRP is a novel therapy that has been tried in such patients. Colombo et al. included eight patients who underwent PRP treatment. The inclusion criteria were women with more than three cancelled cryo-transfers due to poor endometrial growth (<6 mm), women with a negative hysteroscopic screening for endometrial pathology, and women with a

**Omer, 2019, 4 (11)**
negative bacteriologic screening. After application of PRP, the endometrial thickness was satisfactory in seven cases. A positive test for beta-human chorionic gonadotropin was found in six women. They concluded that the multiple implantation failures were caused by inefficient expression of adhesion molecules, which could potentially be improved by PRP application. Similarly, Zadehmodarres et al., in their pilot study, included 10 patients who had a history of cancelled cycles due to inadequate endometrial growth (<7 mm). They found that endometrial thickness increased at 48 hours after the first PRP application and reached more than 7 mm after the second PRP application in all patients. Embryo transfer was then carried out in all patients. Five patients became pregnant (50%), and in four of them the pregnancy progressed normally. They concluded that PRP was effective for endometrial growth in patients with a thin endometrium.

Jang et al., in an animal model, investigated the role of PRP in the regeneration of the endometrium after ethanol-induced damage. They found that intrauterine administration of autologous PRP stimulated and accelerated regeneration of the endometrium, as well as decreasing fibrosis, in a murine model of endometrial damage.

4) PRP in repeated implantation failure

Repeated implantation failure (RIF) is defined as failure to conceive following several embryo transfers in IVF cycles. Numerous factors are involved in the implantation process, including embryo quality, endometrial receptivity, and immunological factors. Several methods have been suggested for RIF management, but little consensus exists on which is most effective. These methods include blastocyst transfer, assisted hatching, hysteroscopy, endometrial scratching, and immune therapy. Recently, the intrauterine infusion of PRP has been described as a way to promote endometrial growth and receptivity. Nazari et al. enrolled 20 participants with a history of RIF to evaluate the effectiveness of PRP in improving the pregnancy rate in RIF patients. The inclusion criteria were being younger than 40 years and having a BMI below 30 kg/m². They reported that 18 of the 20 participants (90%) became pregnant. Sixteen clinical pregnancies were recorded, and their pregnancies were ongoing at the time of the study. They concluded that PRP was effective in improving pregnancy outcomes in RIF patients.

4. PRP in aesthetic gynecology

1) PRP in breast reconstruction

Many studies of PRP have been conducted in the field of aesthetic and plastic surgery, but all were pilot studies, had small samples, or used animal models. PRP together with adipose tissue has been used in breast reconstruction. Gentile et al. enrolled 100 patients aged between 19 and 60 years affected by breast soft-tissue defects. They divided the patients into two equally-sized groups. The study group was treated with fat grafting and PRP, while the control group was treated with fat grafting injections only. They found that the patients treated with PRP added to the autologous fat grafts showed a 69% maintenance rate of the restored contour and of three-dimensional volume after 1 year, whereas the patients in the control group showed a 39% maintenance rate. They concluded that PRP mixed with fat grafts led to improvements in the maintenance of breast volume in patients affected by breast soft-tissue defects. Similar results were obtained by Salgarello et al..

Omer, 2019, 4 (11)
2) PRP in female sexual dysfunction
Platelets have been found to release around 35 growth factors that promote tissue regrowth, healing, and regeneration. This fact has been utilized by aesthetic gynecologists in treatments such as vaginal rejuvenation and O-shot therapy.

1) O-Shot therapy
PRP use in sexual dysfunction is considered to be a revolutionary new nonsurgical outpatient treatment that helps improve both urinary incontinence and sexual dysfunction through using a woman’s own growth factors. The PRP is injected into specific areas of the vagina with the aid of local anesthetic cream. This modality of treatment is called the “O-shot.” PRP immediately activates tissue regeneration, and the enhancement in sexual response is dramatic. The desired response includes improved arousal, stronger orgasm, decreased dyspareunia, and increased natural lubrication.

Runels et al. enrolled 11 women who presented with dyspareunia. They injected PRP into the clitoris and vagina, and found that intravaginal and intraclitoral PRP injections could be an effective method to treat certain types of female sexual dysfunction, especially in the areas of desire, arousal, lubrication, and orgasm.

2) Vaginal rejuvenation
Aesthetic practitioners have used PRP for the regeneration of vaginal mucosa, muscles, and skin. After PRP injection, vaginal vascularity is increased, with a subsequent dramatic increase in sensitivity. In addition, the skin becomes thicker and firmer, making the vagina look much more youthful. Moreover, the ligaments and muscles supporting the urethra become stronger, alleviating urinary incontinence.

Kim et al. reported the use of PRP in a case of vaginal rejuvenation. They concluded that the application of autologous lipofilling mixed with PRP in a patient with vaginal atrophy produced relief of symptoms and contour restoration. The rejuvenated appearance of the external genitalia provided a pleasing cosmetic outcome to the patient.

5. PRP in premature rupture of membranes
Premature rupture of membranes occurs due to damage and tears in the fetal membrane, leading to congenital infections and poor neonatal outcomes. PRP was tried in an in vitro model to evaluate the ability of PRP to seal iatrogenic fetal membrane defects. This was done using single- and double-layer amnion models. The PRP plug was stable and attached firmly to the amnion tear. The authors concluded that they found experimental evidence that a PRP plug persisted for nearly 2 months in an amniotic fluid environment. It also provided waterproof sealing of iatrogenic defects in the amnion and chorion. Moreover, PRP stimulates cell growth and proliferation, and may thereby enhance the membrane-healing response.

Conclusion
PRP is an innovative therapeutic modality, as it is affordable, simple, easily performed, and effective. It is also a noninvasive modality with promising results and no side effects. In the field of gynecology, the few studies that have been conducted are pilot studies, case series, and case reports. The risks of PRP therapy as infection, bleeding, and nerve damage, appear to be minimal. Large randomized controlled studies are required to confirm its efficacy and safety in various gynecological disorders.

Omer, 2019, 4 (11)
References


Omer, 2019, 4 (11)


Omer, 2019, 4 (11)